180 related articles for article (PubMed ID: 23918300)
1. YKL-40 expression could be a poor prognostic marker in the breast cancer tissue.
Kang EJ; Jung H; Woo OH; Park KH; Woo SU; Yang DS; Kim AR; Lee JB; Kim YH; Kim JS; Seo JH
Tumour Biol; 2014 Jan; 35(1):277-86. PubMed ID: 23918300
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer.
Kim SH; Das K; Noreen S; Coffman F; Hameed M
World J Surg Oncol; 2007 Feb; 5():17. PubMed ID: 17286869
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers.
Shao R; Cao QJ; Arenas RB; Bigelow C; Bentley B; Yan W
Br J Cancer; 2011 Oct; 105(8):1203-9. PubMed ID: 21934681
[TBL] [Abstract][Full Text] [Related]
4. YKL-40 expression in soft-tissue sarcomas and atypical lipomatous tumors. An immunohistochemical study of 49 tumors.
Harving ML; Christensen LH; Ringsholt M; Lausten GS; Petersen MM
Acta Orthop; 2014 Apr; 85(2):195-200. PubMed ID: 24650028
[TBL] [Abstract][Full Text] [Related]
5. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study.
Senetta R; Duregon E; Sonetto C; Spadi R; Mistrangelo M; Racca P; Chiusa L; Munoz FH; Ricardi U; Arezzo A; Cassenti A; Castellano I; Papotti M; Morino M; Risio M; Cassoni P
PLoS One; 2015; 10(4):e0123759. PubMed ID: 25875173
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer.
Bi J; Lau SH; Lv ZL; Xie D; Li W; Lai YR; Zhong JM; Wu HQ; Su Q; He YL; Zhan WH; Wen JM; Guan XY
Hum Pathol; 2009 Dec; 40(12):1790-7. PubMed ID: 19765801
[TBL] [Abstract][Full Text] [Related]
7. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer.
Roslind A; Knoop AS; Jensen MB; Johansen JS; Nielsen DL; Price PA; Balslev E
Breast Cancer Res Treat; 2008 Nov; 112(2):275-85. PubMed ID: 18157633
[TBL] [Abstract][Full Text] [Related]
8. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.
Jensen BV; Johansen JS; Price PA
Clin Cancer Res; 2003 Oct; 9(12):4423-34. PubMed ID: 14555515
[TBL] [Abstract][Full Text] [Related]
9. Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer.
Kang EJ; Jung H; Woo OH; Park KH; Woo SU; Yang DS; Kim AR; Lee JB; Kim YH; Kim JS; Seo JH
Neoplasma; 2014; 61(3):352-62. PubMed ID: 24824938
[TBL] [Abstract][Full Text] [Related]
10. YKL-40 expression in human hepatocellular carcinoma: a potential biomarker?
Xiao XQ; Hassanein T; Li QF; Liu W; Zheng YH; Chen J
Hepatobiliary Pancreat Dis Int; 2011 Dec; 10(6):605-10. PubMed ID: 22146624
[TBL] [Abstract][Full Text] [Related]
11. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer.
Yamac D; Ozturk B; Coskun U; Tekin E; Sancak B; Yildiz R; Atalay C
Adv Ther; 2008 Aug; 25(8):801-9. PubMed ID: 18670741
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of the inflammatory protein YKL-40 in precancers of the breast.
Qin W; Zhu W; Schlatter L; Miick R; Loy TS; Atasoy U; Hewett JE; Sauter ER
Int J Cancer; 2007 Oct; 121(7):1536-42. PubMed ID: 17565739
[TBL] [Abstract][Full Text] [Related]
13. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
Johansen JS; Christensen IJ; Riisbro R; Greenall M; Han C; Price PA; Smith K; Brünner N; Harris AL
Breast Cancer Res Treat; 2003 Jul; 80(1):15-21. PubMed ID: 12889595
[TBL] [Abstract][Full Text] [Related]
14. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer.
Johansen JS; Cintin C; Jørgensen M; Kamby C; Price PA
Eur J Cancer; 1995; 31A(9):1437-42. PubMed ID: 7577068
[TBL] [Abstract][Full Text] [Related]
15. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
Diefenbach CS; Shah Z; Iasonos A; Barakat RR; Levine DA; Aghajanian C; Sabbatini P; Hensley ML; Konner J; Tew W; Spriggs D; Fleisher M; Thaler H; Dupont J
Gynecol Oncol; 2007 Feb; 104(2):435-42. PubMed ID: 17023034
[TBL] [Abstract][Full Text] [Related]
16. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer.
Tschirdewahn S; Reis H; Niedworok C; Nyirady P; Szendröi A; Schmid KW; Shariat SF; Kramer G; vom Dorp F; Rübben H; Szarvas T
Urol Oncol; 2014 Jul; 32(5):663-9. PubMed ID: 24814404
[TBL] [Abstract][Full Text] [Related]
17. Expression and clinical significance of YKL-40 protein in epithelial ovarian cancer tissues.
Yang GF; Cai PY; Li XM; Deng HX; He WP; Xie D
Ai Zheng; 2009 Feb; 28(2):142-5. PubMed ID: 19550125
[TBL] [Abstract][Full Text] [Related]
18. High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer.
Wang D; Zhai B; Hu F; Liu C; Zhao J; Xu J
PLoS One; 2012; 7(12):e51127. PubMed ID: 23227243
[TBL] [Abstract][Full Text] [Related]
19. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
[TBL] [Abstract][Full Text] [Related]
20. YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma.
Thongsom S; Chaocharoen W; Silsirivanit A; Wongkham S; Sripa B; Choe H; Suginta W; Talabnin C
Tumour Biol; 2016 Jul; 37(7):9451-63. PubMed ID: 26781979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
